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INTRODUCTION
Treatment with inhaled nitric oxide has been studied as
an adjuvant therapy for a variety of pulmonary conditions.
Because inhaled nitric oxide (NO) acts as a potent selective
pulmonary vasodilator (1) that produces pulmonary vasodi-
latation in well-ventilated lung regions, it can potentially
improve matching ventilation and perfusion (2, 3). Howev-
er, up to 60% of patients with septic acute respiratory dis-
tress syndrome (ARDS) do not respond, or respond only mini-
mally, to inhaled NO with improved oxygenation (4). Recent
reports suggest that increased NO synthesis in the septic lung
causes a poor responsiveness to inhaled NO (5). Attenuation
of hypoxic pulmonary vasoconstriction may be another deter-
minant of the non-response phenomenon to inhaled NO in
the septic lung (6). Some studies have demonstrated that NO-
dependent guanylated cyclase activity plays an important role
in attenuating hypoxic vasoconstriction in the rabbit lung
(7). Fischer et al. (8) reported that nitric oxide synthase inhi-
bition restored hypoxic pulmonary vasoconstriction in sep-
sis. These reports suggest that improvement of oxygenation
with inhaled NO may be augmented by blockade of endo-
genous nitric oxide synthase (NOS) in the setting of increased
NO synthesis in the lung, such as pneumonia (9) or sepsis (10).
Prior studies on the effects of combined treatment, with
blockade of NOS and NO inhalation, have been reported on
both neonatal and adult models of experimental sepsis and
endotoxemia (10-12), where recovery of the systemic blood
pressure by blockade of NOS and simultaneous attenuation of
pulmonary hypertension by NO inhalation were targeted. The
findings show partially beneficial effects and suggest that this
approach deserves further evaluation (11, 12). However, it is
not known whether NOS blockade, in hemodynamically sta-
ble lung injury, is associated with improved oxygenation with
NO inhalation. There are concerns that this approach might
aggravate pulmonary hypertension, induced by NOS blockade,
and compromise further oxygenation, especially in newborns.
We developed a newborn piglet model of Gram-negative
bacterial pneumonia and sepsis by endotracheal instillation
of Escherichia coli previously (13), which is thought to be app-
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Pretreatment with N-nitro-L-arginine Methyl Ester Improved Oxygenation
After Inhalation of Nitric Oxide in Newborn Piglets with 
Escherichia coli Pneumonia and Sepsis
We evaluated the effects of a combined therapy of pre-blockade endogenous nitric
oxide synthase (NOS) with N-nitro-L-arginine methyl ester (L-NAME) and continu-
ous inhaled NO (iNO) on the gas exchange and hemodynamics of Escherichia coli
pneumonia and sepsis in newborn piglets. Seven to ten day old ventilated newborn
piglets were randomized into 5 groups: control, E. coli pneumonia control, pneumonia
with iNO 10 ppm, pneumonia pre-treated with L-NAME 10 mg/kg, and pneumonia
with the combined therapy of L-NAME pretreatment and iNO. E. coli pneumonia
was induced via intratracheal instillation of Escherichia coli, which resulted in pro-
gressively decreased cardiac index and oxygen tension; increased pulmonary vas-
cular resistance index (PVRI), intrapulmonary shunting, and developed septicemia
at the end of 6 hr experiment. iNO ameliorated the progressive hypoxemia and intra-
pulmonary shunting without affecting the PVRI. Only two of 8 animals with L-NAME-
pretreated pneumonia survived. Whereas when iNO was added to infected animals
with L-NAME pretreatment, the progressive hypoxemia was abolished as a result
of a decrease in intrapulmonary shunting without reverse of the high PVRI and sys-
temic vascular resistance index induced by the L-NAME injection. This result sug-
gests that a NOS blockade may be a possible supportive option for oxygenation by
iNO treatment in neonatal Gram-negative bacterial pneumonia and sepsis.
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ropriate to study these concerns. Because confined inflamma-
tion occurs, in the early phase of pneumonia, only in the lung,
animals using this model are more hemodynamically stable
in the early period of experiment than if the lung infection
resulted from sepsis induced by intravenous infusion of bac-
teria. Gram-negative bacterial pneumonia with sepsis is a
common and clinically important pulmonary disease associ-
ated with significant morbidity and mortality rates in humans
including neonates. A recent study has reported that E. coli
is responsible for one half of the early-onset blood stream
infection (BSI) cases among neonates admitted to the neona-
tal intensive care unit (NICU) (14). BSI is a significant risk
factor for the development of ventilator-associated pneumo-
nia in neonates admitted in NICU (15). E. coli is the most
common organism isolated from cultures of lung aspirates
from neonates who are stillborn or die in the first 72 hr of
life in developing countries (16). Therefore this model may
be clinically relevant.
We performed this study to evaluate whether the pretreat-
ment of nitric oxide synthase inhibitor can affect the respons-
es to inhaled NO (iNO) treatment in gas exchange and hemo-
dynamic profiles of newborn piglets with hemodynamically
stable lung injury as a result of E. coli pneumonia and sepsis.
MATERIALS AND METHODS
The protocol was approved by the Research Animal Lab-
oratory Committee of Samsung Biomedical Research Insti-
tute, Seoul, Korea, and the procedures followed were in accord
with institutional guidelines. Studies were performed on 7-
10 day-old newborn piglets of mixed strain (Yorkshir, con-
ventional breed, purchased from Paju farm, Paju, Kyungki-
Do, Korea). Surgical preparation of neonatal piglets was ini-
tiated by sedation with ketamine (20 mg/kg intramuscular
injection) and xylazine (2 mg/kg intramuscular injection)
followed by thiopental anesthesia (5 mg/kg, intravenous in-
jection). After local injection with lidocaine (1%), a tracheo-
stomy was performed and the piglet was paralyzed with pan-
curonium (0.1 mg/kg, intravenous injection.) followed by
hourly intravenous injections. Sedation was maintained with
hourly doses of thiopental. The paralyzed piglet was placed
on a time-cycled pressure-limited infant ventilator (Sechrist
Infant Ventilator, Model IV-100V, Sechrist Industries, Ana-
heim, CA, U.S.A.) to attain an arterial O2 tension of 80-100
mm Hg and an arterial CO2 tension of 35-45 mm Hg. The
right femoral artery was cannulated for arterial blood gas sam-
pling and systemic arterial blood pressure monitoring. The
right femoral vein was cannulated into the right atrium for
infusion of ice-saline to monitor cardiac output which was
calculated by the thermodilution method using the CO-set
(Edwards Lifesciences, Irvine, CA, U.S.A.), and for adminis-
tration of fluids and medications. A 5-Fr. Swan-Ganz catheter
(Baxter Health-care Corp., Irvine, CA, U.S.A.) was inserted
into the right external jugular vein and advanced into the
pulmonary artery using direct-pressure and pressure wave
monitoring. It was used for sampling of mixed venous blood
and measurement of pulmonary arterial wedge pressures. An
infusion of 0.9% saline containing 1 U of heparin/mL was
provided at 1-2 mL/hr through the arterial catheter and the
pulmonary arterial catheter, both of which were attached to
a blood pressure transducer (Hewlett-Packard Model M12-
76A, MA, U.S.A.). A Hewlett Packard neonatal monitoring
system (Hewlett-Packard Model M1276A) continuously
monitored electrocardiogram, oxygen saturation and systemic
arterial and pulmonary arterial pressure. Animals were main-
tained supine with the head of the bed elevated 20 degrees
throughout the study. Constant body temperature was main-
tained between 38-39℃ using a warmed operating table
and servo-controlled overhead heater (Airshields, Neonatal
intensive care unit, Hatboro, PA, U.S.A.). 
Experimental protocol
After surgery and stabilization, baseline measurements of
arterial blood gases and hemodynamic parameters were reco-
rded. Ventilator settings were changed to a peak inspiratory
pressure (PIP) 30 cmH2O, rate 25/min, a peak end expira-
tory pressure (PEEP) 4 cmH2O and an inspiratory time (IT)
of 0.6 sec. Animals were divided into five groups: 1) a sham
operation control group (CON, n=6), 2) an E. coli pneumo-
nia control (PCON, n=10), 3) a pneumonia and nitric oxide
inhalation (PNO, n=10), 4) a N-nitro-L-arginine methyl ester
(L-NAME) treated pneumonia (PNA, n=8) and 5) a L-NAME
treated pneumonia followed by NO inhalation (PNANO,
n=8). After baseline measurements of arterial blood gases,
Escherichia coli pneumonia was induced in all animals except
the CON group. Each anesthetized animal was placed in the
supine position with the head elevated approximately 20
degrees and a 5-Fr. catheter was inserted through the endo-
tracheal tube. The bacterial inoculum of Escherichia coli, EC69
strain (kind gift of Dr. Kwang Sik Kim, Johns Hopkins Uni-
versity, Baltimore, Maryland, U.S.A.) (17), 1×109 colony
forming unit in 10 mL of 0.9% saline was instilled into the
lung followed by a 10 mL bolus of air to disperse the bacte-
ria into the distal lung. Piglets in the CON group were given
10 mL of 0.9% saline instead of the bacterial inoculum. The
experimental protocols for each group are described in Fig. 1.
L-NAME, a nonselective inhibitor of nitric oxide synthase
was injected 30 min before bacterial instillation in the PNA
and PNANO groups. Nitric oxide gas, 10 ppm inhalation,
was started at 30 min after bacterial instillation and contin-
ued until the end of the experiment in the PNO and PNANO
groups. The animals were maintained for 6 hr after the bac-
terial or saline instillations. Blood cultures were obtained,
for each animal, at the end of experiment. L-NAME and iNO in Neonatal Pneumonia and Sepsis 967
Cardiopulmonary measurements
Heart rate (HR), mean arterial pressure (MAP, mmHg),
mean pulmonary arterial pressure (PAP, mmHg), and cardiac
output (mL/min) were measured by the femoral arterial and
thermodilution pulmonary arterial catheters. Hemodynamic
data were indexed to body weight in kilograms. The cardiac
index (CI), systemic vascular resistance index (SVRI) and pul-
monary vascular resistance index (PVRI) were calculated using
standard formulas.
Intrapulmonary right-to-left shunting was calculated by
the Fick equation (Ca-Cc/Cv-Cc). CcO2, CaO2 and CvO2 rep-
resent the oxygen content of the pulmonary capillary blood,
the arterial blood and the mixed venous blood, respectively.
PaO2 and PaCO2 were measured from the arterial and mixed
venous blood samples taken from the femoral arterial catheter
and from the pulmonary arterial catheter. Alveolar capillary
O2 content (CcO2) was calculated using PAO2 (partial pres-
sure of oxygen in the alveoli) from the alveolar gas equation
with PAO2=[(BP-47)×(FiO2)]-PaCO2. Blood gases were
analyzed using a blood gas analyzer (Ciba-Corning Diagnos-
tics Corp., Medfield, MA, U.S.A.) and oxygen saturation was
measured with a hemoximeter, which adjusted the oxygen
saturation to the specific hemoglobin of a pig. Concentrations
of lactate were measured using an YSI model 2300 dual ana-
lyzer (Yellow Springs Instrument Co., Yellow Springs, OH,
U.S.A.).
Expiratory CO2 (PECO2) was measured, analyzed and stan-
dardized with a known concentration of CO2 on the expira-
tory side (mainstream) of the circuit’s endotracheal tube con-
nector using a CO2SMO (Novametrix Medical Systems Inc.
Wallingford, CT, U.S.A.). PECO2 measurements and ABGA
were simultaneously determined. The arterial end-tidal dif-
ference {P(a-E)CO2} was obtained by subtracting the PECO2
from PaCO2 of an arterial blood sample obtained during the
sampling period. The dead space/tidal volume ratio (Vd/Vt
ratio), as PaCO2-PECO2/PaCO2, was calculated using the
Bohr-Enghoff method and was expressed as a ratio of tidal
volume (18).
All measurements were recorded at baseline, 0 hr and sub-
sequently every hour after bacterial or saline instillation thro-
ugh the trachea. 
Statistical methods
Normality test for each variable was done. Continuous
variables with normal distribution were presented as mean
±SD, which was analyzed by repeated-measures analysis of
variance (ANOVA) within groups and compared by a one-
way ANOVA with post hoc testing with the Bonferroni cor-
Stabilization E. coli Pneumonia
Ventilator re-adjustment
End of Experiment iNo E. coli/Saline L-NAME Surgery
Measurement (hr)
Surgical control (n=6)
CON
30 min 30 min 30 min 6 hr
1 0
-1
2 3 456
iNo (10 ppm)
Pneumonia control (n=10)
PCON
Pneumonia+iNO (10 ppm) (n=10)
PNO
L-NAME pretreatment+Pneumonia (n=8)
PNA
L-NAME pretreatment+Pneumonia+iNO (10 ppm) (n=8)
PNANO
Fig. 1. Scheme of the experimental protocol. L-NAME, administration of N-nitro-L-arginine methyl ester; E.coli/Saline, intratracheal instilla-
tion of Escherichia coli or Saline; iNO, administration of inhaled nitric oxide; Ventilator re-adjustment, Ventilator settings were changed to
peak inspiratory pressure (PIP) 30 cmH2O, rate 25/min, peak end expiratory pressure (PEEP) 4 cmH2O, inspiratory time (IT) 0.6 sec. Ani-
mals in PNA were not included for the results because only two of eight survived. Measurement of variables was recorded hourly.968 Y.S. Chang, S. Kang, S.Y. Ko, et al.
rection from each group at the same point. Variables with-
out showing normal distribution were presented as median
with range and analyzed by Kruskal-Wallis analysis of vari-
ance with the Bonferroni correction to detect the differences
among the groups, where appropriate. All data analysis used
the SAS software program, SAS Enterprise Guide 3.0 (SAS
Institute Inc., Cary, NC, U.S.A.). p values below 0.05 were
considered significant.
RESULTS
Prior to the study, no differences were observed among five
groups of animals for body weight (CON group 4.2±0.4 kg,
PCON group 4.6±0.7 kg, PNO group 4.3±0.5 kg, PNA
group 4.6±0.9 kg, PNANO group 4.5±0.7 kg) and total
hemoglobin concentration (CON group 11.3±1.1 g/dL, PC-
ON group 11.6±2.4 g/dL, PNO group 11.1±1.4 g/dL,
PNA group 11.8±2.5 g/dL, PNANO group 12.0±4.4
g/dL). Hemoglobin remained constant in all groups through-
out the study period.
Sepsis and survival
All infected animals had positive results for Escherichia coli
on blood cultures from blood taken at the end of the experi-
ment. All piglets in the CON, PCON and PNANO groups
and 9/10 (90%) in PNO group survived, whereas 6/8 (75%)
piglets in the PNA group died to the end of the experiment.
Animals pretreated with L-NAME without NO inhalation
were observed to be very unstable. They had very short sur-
vival times using this protocol. Therefore, we were unable to
include the PNA group in the following data analysis.
Surgical control
The surgical control animals, with intratracheal instillation
of saline, did not show any significant changes in heart rate,
arterial blood lactate and pH, systemic and pulmonary hemo-
Baseline 3 6
Heart Rate (/min)
a
CON 136±17 130±10 146±33
PCON 143±25 136±20 173±70
PNO 144±27 157±42 156±44
PNANO 148±29 128±26 162±66
Arterial pH
b
CON 7.58 (7.37-7.59) 7.53 (7.48-7.63) 7.62 (7.41-7.68)
PCON 7.63 (7.37-7.70) 7.36 (7.00-7.48) 7.31 (6.76-7.43)*
PNO 7.54 (7.48-7.68) 7.28 (6.65-7.57)* 7.38 (6.96-7.51)
PNANO 7.62 (7.43-7.72) 7.23 (7.11-7.37)* 7.22 (6.88-7.34)*
Lactate (mM/L)
b
CON 0.75 (0.60-1.58) 0.79 (0.51-1.23) 0.69 (0.43-0.99)
PCON 0.73 (0.51-2.62) 0.88 (0.52-3.96) 0.65 (0.20-5.07)
PNO 0.91 (0.72-1.31) 0.97 (0.44-4.65) 0.80 (0.43-1.65)
PNANO 1.08 (0.62-4.52) 3.28 (1.65-7.28)*
,� 3.82 (1.95-5.56)*
,�
Table 1. Physiologic values and blood lactate level at baseline,
3 and 6 hr after intratracheal E. coli Instillation
Values given present; ‘‘a’’ as means±SD and ‘‘b’’ as median (range).
*p<0.05 vs. CON, 
� p<0.05 vs. PCON.
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Fig. 2. Mean systemic arterial pressure (MAP), mean pulmonary arterial pressure (PAP), mean systemic vascular resistance index (SVRI),
mean pulmonary vascular resistance index (PVRI) and cardiac index in the newborn piglets of 4 groups at -1, 0, 3, and 6 hr of experiment. 
CON: control group; PCON: E. coli pneumonia control; PNO: E. coli pneumonia with 10 ppm nitric oxide inhalation; PNANO: E. coli pneu-
monia with added nitric oxide inhalation to L-NAME pretreatment (10 mg/kg). Data represent mean±standard deviation. *p<0.05 com-
pared to CON, 
� p<0.05 compared to PCON. 
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dynamics or gas exchange during the entire period of exper-
iment. 
Heart rate, arterial blood lactate and pH 
Arterial pH decreased progressively after E. coli instillation
through the trachea. Nitric oxide inhalation (PNO) did not
ameliorate this change in infected animals. Infected animals
with L-NAME pre-treatment and iNO (PNANO) showed
significantly higher lactate level at 6 hr compared to the ani-
mals of PCON and PNO groups (p<0.05) (Table 1).
Systemic hemodynamic variables 
Infected animals, with E. coli, did not show significant
change in the mean arterial pressure (MAP) compared to the
surgical control animals during the entire 6-hr period of the
experiment (Fig. 2). PNANO animals showed marked and
significant increase in MAP right after L-NAME injection;
this continued 1 hr after bacterial instillation compared to
the other groups (p<0.01). The cardiac index significantly
decreased from 1 hr through 3 hr after bacterial instillation
in all infected animals compared to the surgical controls (CON)
(p<0.05). A greater decrease in cardiac index was observed
in the PNANO animals compared to the PCON group from
0 hr to the end of the experiment (p<0.05), and when com-
pared to the PNO group from 3 hr to 5 hr after bacterial in-
stillation (p<0.05). SVRI increased slightly in the PCON and
the PNO groups at 2 and 3 hr after bacterial instillation. How-
ever, a marked increase in the SVRI was observed in the PN-
ANO group right after the L-NAME injection and through-
out the experiment compared to the other groups (p<0.01). 
Pulmonary hemodynamic variables 
Pulmonary arterial pressure (PAP) increased markedly and
significantly in the PNANO animals right after L-NAME
injection, until 1 hr after bacterial instillation (p<0.01); it
remained higher compared to the CON group throughout
the experiment (p<0.05) (Fig. 2). The other groups did not
show an increase in the PAP. However when we calculated
the pulmonary vascular resistance index (PVRI), there was a
statistically significant increase in PVRI in all pneumonia groups
(PCON, PNO, and PNANO) compared to the surgical con-
trols for 3 hr after bacterial instillation (p<0.05). PVRI in-
creased significantly for the PNANO group compared to the
Fig. 3. Arterial oxygen tension, carbon dioxide tension, intrapulmonary shunt fraction (venous admixture %) and Vd/Vt (dead space to tidal
volume ratio) in the newborn piglets of 4 groups at 0, 3, and 6 hr of experiment.
CON: control group; PCON: E. coli pneumonia control; PNO: E. coli pneumonia with 10 ppm nitric oxide inhalation; PNANO: E. coli pneu-
monia with added nitric oxide inhalation to L-NAME pretreatment (10 mg/kg). Data represent mean±standard deviation. *p<0.05 com-
pared to CON, 
� p<0.05 compared to PCON, 
� p<0.05 compared to PNO.
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PCON and PNO right after L-NAME injection and remained
high during the entire experimental period (p<0.01). NO
did not decrease the PVRI to baseline in either the PNANO
or the PNO animals. There were no differences in the PVRI
in the PNO and the PCON animals after bacterial instillation. 
Gas exchange 
PaO2 values in all groups, at the start of experiment, were
in excess of 500 mmHg; the final PaO2 value was 460±28
mmHg in the surgical control animals (CON). Bacterial in-
stillation through the trachea induced a progressive and signif-
icant decrease in the PaO2 level, which was 178±40 mmHg
in the PCON animals at the end of experiment (p<0.01, by
one-way repeated-measures ANOVA). NO inhalation ame-
liorates the progressive decrease in PaO2 in infected animals
(PNO) (360±27 mmHg at the end of experiment, p<0.05
vs. PCON and CON). Pretreatment with L-NAME, before
NO inhalation, (PNANO) completely prevented the pro-
gressive decrease in PaO2 (412±26 mmHg at 6 hr, p not
significant by one-way repeated-measures ANOVA; p not
significant vs. CON, p<0.05 vs. PCON) (Fig. 3).
PaCO2 levels were slightly increased from 25±1 mmHg
at 0 hr to 31±2 mmHg at the end of the experiment in sur-
gical controls; however, this did not reach statistical signifi-
cance by one-way repeated measures ANOVA over time. Bac-
terial instillation through the trachea increased the PaCO2
level progressively (p<0.05, by one-way repeated-measures
ANOVA), and the PaCO2level increased from 27±1 mmHg
at 0 hr to 57±7 mmHg at the end of the experiment for
the PNO animals (p<0.05 vs. CON). INO did not affect the
PaCO2 level in the infected animals (52±6 mmHg at 6 hr
in PNO; p<0.05 vs. CON; p not significant vs. in PCON).
However, the PNANO animals did not show this progres-
sive increase in the PaCO2 level (pnot significant by one-way
repeated-measures ANOVA); the PaCO2 level, at the end of
experiment, was not significantly different from that of the
CON animals (47±5 mmHg, pnot significant).
For the surgical control animals, venous admixture or per-
cent intrapulmonary shunting did not change during the
experiment (5±1% at 0 hr, 6±1% at 6 hr). However, bac-
terial instillation through the trachea increased the percent of
intrapulmonary shunting progressively; the percent of shunt-
ing was 17±6% at the end of experiment in the PCON
group (p<0.05 vs. CON). iNO prevented this progressive
increase in percent of intrapulmonary shunting in the infect-
ed animals. The percent of intrapulmonary shunting decreased
significantly at 5 and 6 hr during the experiment in the PNO
animals, and at 3, 4, 5, 6 hr in the PNANO animals com-
pared to the PCON group (p<0.05). No significant changes
in the alveolar dead space volume (corrected Vd/Vt) were ob-
served in all experimental groups. However a significantly
decreased corrected Vd/Vt value was observed at 3 and 4 hr
after bacterial instillation only in the PNANO group when
compared to the PCON group (p<0.05). 
DISCUSSION
We have demonstrated that L-NAME pretreatment poten-
tiates the effect of NO inhalation, especially oxygenation in
a newborn piglet model of E. coli pneumonia and sepsis. Aug-
mented oxygenation, during iNO with pretreated L-NAME
in infected animals, did not result from stabilization of circu-
latory instability or restoration of low blood pressure by L-
NAME pre-treatment. This is because this newborn piglet
model of E. coli pneumonia was not accompanied by circula-
tory collapse during the 6-hr study period. The study effects
were associated with augmented gas exchange, complete dec-
rease in intrapulmonary shunting and partial decrease in the
relative dead space during ventilation of the infected animals
as a result of combined treatment with pre-blockade of NOS
and iNO, which was more pronounced when compared to
infected animals treated with iNO only. In this model of pneu-
monia and sepsis, there was no significant changes observed
in systemic and pulmonary arterial pressure during the 6-hr
study period after intratracheal instillation of bacteria, how-
ever, there was a minor decrease in cardiac index, which caused
a slight increase in SVRI and PVRI. INO did not affect the
systemic and pulmonary hemodynamics. This is likely due
to iNO not alleviating the decreased cardiac index. A decreased
cardiac index might have resulted from gradual decrease in
arterial pH in our study model. Further decrease in the car-
diac index in the PNANO group might have resulted from
aggravated systemic vasoconstriction and lactic acidosis from
L-NAME pretreatment. The observed NO-related changes
in oxygenation, that were seen in this piglet model with Gram-
negative pneumonia and sepsis, are consistent with findings
of clinical studies of acute respiratory distress syndrome, show-
ing that inhaled NO may improve oxygenation without ob-
served changes in pulmonary arterial pressure (19). 
L-NAME pretreatment, in infected animals, was not com-
patible with survival and only two of 8 animals survived in
that study group. This is consistent with our previous study.
In that study we demonstrated that nonselective inhibition
of NOS only is detrimental in the early phase of experimen-
tal neonatal sepsis (20). However, differences from this study
are model used. In previous study sepsis was induced by int-
ravenous injection of E. coli, which showed systemic hypoten-
sion (20). However in this study we used pneumonia and
sepsis model without systemic hypotension, which was in-
duced by intratracheal instillation of E. coli. 
Hypoxemia during pneumonia, and other lung injury,
results in large part from mismatch of perfusion and venti-
lation (21). Hypoxic pulmonary vasoconstriction (HPV), the
normal physiological response that diverts blood flow from
poorly to well-ventilated lung regions, has been shown to be
impaired in patients with pneumonia, sepsis or the acute res-L-NAME and iNO in Neonatal Pneumonia and Sepsis 971
piratory distress syndrome (22). This attenuation of HPV
increases intrapulmonary shunting that results in systemic
hypoxemia (8, 22, 23). Nitric oxide is known as one of the
vasoactive mediators that alter pulmonary vascular tone dur-
ing lung inflammation (24). Endogenous NO is produced
by three different isoforms of nitric oxide synthase (NOS)
that have been characterized as neuronal (NOS1), inducible
(NOS2) and endothelial (NOS3) forms (25). Transcription-
ally regulated NOS2-derived NO production reduces the
pulmonary responsiveness to exogenous inhaled NO, alters
pulmonary blood flow distribution, and impairs arterial oxy-
genation in endotoxin challenged mice (26).
Some possible explanations for this beneficial effect on oxy-
genation of L-NAME pretreatment added to NO inhalation
are as follows. Previously, Fischer et al. has reported that NOS
inhibition partly restores HPV in sepsis (8). In healthy animals,
NOS inhibitors augment HPV (27). Very little is known,
however, about the effect of NOS inhibitors on HPV in sep-
sis or pneumonia. Maurenbrecher et al. (6) has reported that
response to inhaled NO is abolished over time and that this
non-response to inhaled NO is likely to be related to the deg-
ree of V/Q mismatch. This may suggest an important role
of HPV in endotoxin-induced lung injury. Recently Spohr
et al. demonstrated that, in a murine model of endotoxemia,
NOS2-derived NO production is critical for LPS-mediated
development of impaired HPV (28).
In the pneumonia and sepsis model used in this study intra-
pulmonary shunting increased and arterial oxygen tension
decreased progressively with time. Inhaled NO effectively
decreased this V/Q mismatch, which resulted in amelioration
of progressive hypoxemia. Inhaled NO added to L-NAME
pretreatment, in infected animals, showed earlier and maxi-
mal decrease in intrapulmonary shunting. A previously pub-
lished study by Putensen et al. (29) supports our findings.
They demonstrated that in oleic acid-induced lung injury, in
an adult canine model, improved ventilation-perfusion match-
ing and gas exchange was most pronounced when NO was
inhaled in the presence of systemic N-monomethyl-L-argi-
nine (L-NMMA), a non-selective NOS inhibitor. Therefore,
L-NAME pretreatment might restore HPV via inhibition
of excessive production of endogenous nitric oxide, especial-
ly by NOS2, which augmented improved oxygenation with
inhaled NO in our experimental model of neonatal pneumo-
nia and sepsis.
A second plausible explanation is that L-NAME might
attenuate a microvascular leak from a ventilator induced lung
injury (VILI). A recent report suggested that L-NAME may
attenuate ventilator-induced microvascular leaks and lipid
peroxidation, and that NO may contribute to the develop-
ment of VILI (30). In our experiment, all animals were ven-
tilated with re-adjusted settings of high PIP, and high oxy-
gen concentration right after bacterial or saline instillation.
This was done to avoid significant hypoxemia that could
cause additional deterioration of pulmonary hemodynamics.
Therefore although the experiment duration was 6 hr, some
degree of VILI, as a result of high ventilator settings, might
have contributed to the lung injury especially in infected ani-
mals. L-NAME has a long plasma half-life of about 22 hr (31).
In our pneumonia model, L-NAME pretreatment added to
iNO, ameliorated hypercapnea and partly decreased the ratio
of dead space to tidal volume. Therefore, there is a possibility
that NOS blockade might blunt VILI during the study peri-
od, and potentiate the effect of inhaled NO in this model. 
In summary, intratracheal E. coli instillation in newborn
piglets resulted in progressive hypoxemia and hypercapnea
with relatively minor changes in pulmonary and systemic
hemodynamics. In this model of experimental neonatal Gram-
negative bacterial pneumonia and sepsis, inhaled NO atten-
uated progressive hypoxemia via decrease in intrapulmonary
shunting, but did not affect the increase in PVRI. Prior non-
specific NOS blockade, with L-NAME and treatment with
exogenous iNO, resulted in resolution of progressive hypox-
emia in this pneumonia and sepsis model and improved hy-
percapnea partially, although it was associated with aggra-
vated elevation of PVRI and SVRI. Extrapolation of these
findings to the clinical setting, suggest that iNO may have
a limited therapeutic role in acute lung injury associated with
neonatal Gram-negative bacterial pneumonia and sepsis. En-
dogenous NOS blockade may be a possible option for enhan-
cement of inhaled NO, improving gas exchange in acute lung
injury associated with neonatal Gram-negative bacterial pne-
umonia and sepsis. 
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